ArticleMolecular neurobiology2025
Neuroprotective Effects of Catechins by Differentially Affecting the Binding of Beta-amyloid and Its Aggregates to the Target Cells.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aggregation and deposition of amyloid-β protein (Aβ42) in extracellular spaces are key neuropathological features of Alzheimer's disease (AD). Extracellular Aβ42 aggregates not only impair the function of the extracellular matrix but also directly damage brain cells through binding interactions. Chemically, tea polyphenols are amphiphilic, similar to the Aβ42 molecule. This study found that catechin (CA) and epigallocatechin gallate (EGCG) effectively bound to Aβ42 monomers (Aβ42M) and oligomers (Aβ42O), preventing Aβ42 aggregation; in contrast, EGCG also showed some binding to protofibrils (Aβ42P) and fibrils (Aβ42F), slightly inhibiting their development. In the presence of Aβ42M and Aβ42 aggregates in vitro, CA and EGCG demonstrated considerable protective effects on neural and vascular endothelial cells. These effects corresponded with the ability of CA and EGCG (particularly CA) to preserve Aβ42M's targeting and binding to these cells, while they (especially EGCG) blocked or inhibited Aβ42O's targeting and binding. Molecular docking revealed that both CA and EGCG effectively maintained the active conformation of Aβ42M; in contrast, EGCG also effectively rendered Aβ42O units inactive, primarily by disrupting and covering the hydrophobic clusters. Furthermore, CA and EGCG improved the AD brain microenvironment, including reducing Aβ42 plaque burden and supporting brain cell populations. In conclusion, CA and EGCG inhibited the structure, bioactivity, and cell-targeting ability of Aβ42 aggregates; however, they protected these aspects of Aβ42M. These findings are essential for understanding the neuroprotective mechanisms of plant polyphenols.
Indexed as
Identifiers
40172817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.